Involvement of autocrine CXCL12/CXCR4 system in the regulation of ovarian carcinoma cell invasion

Biochemical and Biophysical Research Communications

Volumn 403, Issue 1, 2010, Pages 154-159

  Miyanishi, Nami ^a   Suzuki, Yukino ^a   Simizu, Siro ^a   Kuwabara, Yoshiko ^a   Banno, Kouji ^a   Umezawa, Kazuo ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Chemokine; Invasion; MMP; NF B

Indexed keywords

AMPHIREGULIN; CHEMOKINE RECEPTOR CXCR4; CXCL16 CHEMOKINE; DEHYDROXYMETHYLEPOXYQUINOMICIN; DIPEPTIDYL PEPTIDASE IV; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; GELATINASE B; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PENTRAXIN 3; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 4; UROKINASE; VASCULOTROPIN;

ARTICLE; CARCINOMA CELL; CELL INVASION; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEOMICS;

ANTINEOPLASTIC AGENTS; AUTOCRINE COMMUNICATION; CARCINOMA; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL12; FEMALE; HUMANS; NEOPLASM INVASIVENESS; NF-KAPPA B; OVARIAN NEOPLASMS; RECEPTORS, CXCR4; SMALL MOLECULE LIBRARIES;

EID: 78649700451     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.11.007     Document Type: Article

References (28)

1. American Cancer Society Cancer Facts & Figures 2007, American Cancer Society Inc., Atlanta, GA, 2007.
2. Kristensen G.B., Trope C. Epithelial ovarian carcinoma. Lancet 1997, 349:113-117.
3. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Eng. J. Med. 2006, 354:34-43.
4. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
5. Aznavoorian S., Murphy A.N., Stetler-Stevenson W.G., Liotta L.A. Molecular aspects of tumor cell invasion and metastasis. Cancer 1993, 71:1368-1383.
6. Moser T.L., Young T.N., Rodriguez G.C., et al. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int. J. Cancer 1994, 56:552-559.
7. Fishman D.A., Bafetti L.M., Banionis S., et al. Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer 1997, 80:1457-1463.
8. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
9. Horuk R. Chemokine receptors. Cytokine Growth Factor Rev. 2001, 12:313-335.
10. Müller A., Homey B., Soto H., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56.
11. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin. Cancer Biol. 2004, 14:171-179.
12. Chilov D., Kukk E., Taira S., et al. Genomic organization of human and mouse genes for vascular endothelial growth factor C. J. Biol. Chem. 1997, 272:25176-25183.
13. Helbig G., Christopherson K.W., Bhat-Nakshatri P., et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem. 2003, 278:21631-21638.
14. Matsumoto N., Ariga A., To-e S. Et al., Synthesis of NF-κB activation inhibitors derived from epoxyquinomicin C. Bioorg. Med. Chem. Lett. 2000, 10:865-869.
15. Ariga A., Namekawa J., Matsumoto N., Inoue J., Umezawa K. Inhibition of tumor necrosis factor-α-induced nuclear translocation and activation of NF-κB by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 2002, 277:24625-24630.
16. Takatsuna H., Asagiri M., Kubota T., et al. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-κB inhibitor, through downregulation of NFATc1. J. Bone Miner. Res. 2005, 20(2005):653-662.
17. Matsumoto G., Namekawa J., Muta M., et al. Targeting of nuclear factor κB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: antitumor and antiangiogenic potential in vivo. Clin. Cancer Res. 2005, 11:1287-1293.
18. Starenki D.V., Namba H., Saenko V.A., et al. Induction of thyroid cancer cell apoptosis by a novel nuclear factor κB inhibitor, dehydroxymethylepoxyquinomicin. Clin. Cancer Res. 2004, 10:6821-6829.
19. Ohsugi T., Horie R., Kumasaka T., et al. In vivo antitumor activity of the NF-κB inhibitor dehydroxymethylepoxyquinomicin in a mouse model of adult T-cell leukemia. Carcinogenesis 2005, 26:1382-1388.
20. Suzuki Y., Sugiyama C., Ohno O., Umezawa K. Preparation and biological activities of optically active dehydroxymethylepoxyquinomicin, a novel NF-κB inhibitor. Tetrahedron 2004, 60:7061-7066.
21. Dignam J.D., Lebovitz R.M., Roeder R.G. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucl. Acids Res. 1983, 11:1475-1489.
22. Koizumi K., Hojo S., Akashi T., Yasumoto K., Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007, 98:1652-1658.
23. Scotton C.J., Wilson J.L., Milliken D., Stamp G., Balkwill F.R. Epithelial cancer cell migration: a role for chemokine receptors?. Cancer Res. 2001, 61:4961-4965.
24. Pistoia V., Corcione A., Dallegri F., Ottonello L. Lymphoproliferative disorders and chemokines. Curr. Drug Targets 2006, 7:81-90.
25. Jiang Y.P., Wu X.H., Shi B., Wu W.X., Yin G.R. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol. Oncol. 2006, 103:226-233.
26. Kajiyama H., Shibata K., Terauchi M., et al. Involvement of SDF-1α/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer 2008, 122:91-99.
27. Miyazaki I., Simizu S., Ichimiya H., Kawatani M., Osada H. Robust and systematic drug screening method using chemical arrays and the protein library: identification of novel inhibitors of carbonic anhydrase II. Biosci. Biotechnol. Biochem. 2008, 72:2739-2749.
28. Bonizzi G., Bebien M., Otero D.C., et al. Activation of IKKα target genes depends on recognition of specific κB binding sites by RelB:p52 dimers. EMBO J. 2004, 23:4202-4210.